Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. - Test2 - elhamkhani - TriplyDB

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

http://www.wikidata.org/entity/Q34193953

about

De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma HPV Associated Head and Neck Cancer HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer Biomarkers of head and neck cancer, tools or a gordian knot?HPV Carcinomas in Immunocompromised Patients The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer HPV in oropharyngeal cancer: the basics to know in clinical practice Human papilloma virus infection in head and neck cancer Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer An updated overview of HPV-associated head and neck carcinomas Is radiation dose reduction the right answer for HPV-positive head and neck cancer?What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials.p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or ..Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand Aurora kinases in head and neck cancer Management of Oropharyngeal Cancer in the HPV Era.Clinical features and treatment strategy for HPV-related oropharyngeal cancer.Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.p16, Cyclin D1, and HIF-1α Predict Outcomes of Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Definitive Intensity-Modulated Radiation Therapy.¹⁸F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data.Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site - current status and challenges.A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas.Unilateral neck therapy in the human papillomavirus ERA: accepted regional spread patterns.Clinical update on cancer: molecular oncology of head and neck cancer High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods.Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review.Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy Designing biomarker studies for head and neck cancer.Clinical and scientific impact of human papillomavirus on head and neck cancer.The molecular balancing act of p16(INK4a) in cancer and aging.Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer.Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.

P2860

Q24200362-BAC4A0F2-E8F4-47C3-8620-831DBF4F9FAE Q26741386-0B09A1C5-A429-4900-B1D6-977A9486C88D Q26752584-2BDBF227-A805-4676-9F8A-A98F172D6E8D Q26782255-093DA988-183C-4E7C-AD69-CEB142BCC1D5 Q26784289-581521E3-BC5B-48EC-BBE8-F482EA9D5292 Q26799629-75A7FED9-4454-4E26-8A1D-57FB09FB9604 Q26830495-B615D591-BDC4-416C-911D-DC1673C1DD1C Q26852215-375BAC4D-BCBF-4899-A58C-7E13B843001A Q26853669-D49E9AE1-A0AA-49AF-9662-0C700B662FD9 Q26996504-2DEB5A24-AD76-440A-8334-09C05E0B06D2 Q27009148-CEE2F928-7900-495B-BEBD-553942C8502B Q27014019-1A3A8EF2-A828-46FE-A5D5-1185F207FDFB Q27024764-AC7F2601-9456-45DB-A732-C472A36D0C08 Q27026269-7149BB6A-C3C5-48E9-8054-5E9E6B74CACD Q27853003-AD7E2057-2B97-40D7-9152-FE9B9F294C99 Q27853077-7C3153E2-DD68-4B99-8943-C11A02F87F3B Q27853173-8B78739F-6BFB-47F9-9064-56A715DC5C80 Q27853302-82E1A67E-5265-47BC-84AE-031C4DD078ED Q28085180-C872D94A-A565-45A0-A580-B77A25BDA7BA Q28654389-C501C9A1-A49E-44E8-980B-180CF54C8BE3 Q30248326-D93FEF87-62E7-496E-9F3C-4E958A24D5A6 Q30249150-2A3BA9AB-954C-47ED-BB11-DE2C02A02A82 Q30252081-DD2FA927-E1BA-489D-8743-DD88E1AA267D Q30373904-64B755B5-6D29-4BD4-B2D1-9889D5FDF970 Q30425570-9D4E602B-F7A4-4675-9207-333C7F443E1E Q30980315-6D8FE9FC-1B76-4736-8052-F9FE58B6F434 Q33655046-604944F3-14C1-4107-8D45-1A95A9728E90 Q33679518-0F161C9D-98C9-4A4A-94DA-4347A1741D00 Q33682653-C01CF432-471D-4CBA-A036-0CC0646CCD7B Q33695197-76517FB5-0729-4F2D-9712-5EBEB66D174E Q33726331-B3C81F95-7D5C-45F4-8A8F-7A3DAD241770 Q33770030-AD87EEA0-226A-45E4-8196-2DB4F37A5D6D Q33884484-4C564C4B-0219-4B7E-BED6-9927F6A339C9 Q33971467-0C0CDCDB-4C01-43BB-BCEC-2383D3A2CBC8 Q34031281-05FEF15B-A0D8-4068-9CAA-9AD06402F3C6 Q34038585-D670369A-3ECB-4CC9-BCD1-9265F07742D6 Q34106680-83F41474-2346-4E99-92EB-0759F374F423 Q34202289-C903D523-6B78-43E5-B82F-98C3368678C7 Q34232203-66EA4D89-7531-47F3-B4DF-D9984ED2546B Q34394972-CE7222E6-86F4-47B3-B208-70F360489CA0

P2860

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

http://www.wikidata.org/entity/Q34193953

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@ast

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@en

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@nl

type

label

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@ast

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@en

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@nl

prefLabel

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@ast

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@en

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@nl

P1433

Q34193953-F2F3AA6B-4AB9-40E8-B013-D11B7DCB4224

P1476

Q34193953-A8954DE4-83EC-4F1A-89DB-8E78956043B5

P2093

Q34193953-00E9B6CF-3EDD-4DCE-84E5-F98395900203

Q34193953-0FDAE675-19F3-4B69-BD76-65F04405A525

Q34193953-1D9A559A-E492-488A-B624-C7242AC943E3

Q34193953-52D2E9D4-21FE-42EF-A3D9-330A718EE8AE

Q34193953-63693145-812B-45CC-AD18-C3F1E8DF9364

Q34193953-D83FB8FE-659E-4308-B0E4-49410E81A7D1

Q34193953-EDE11200-B5CF-4405-8A84-223ED6684B5E

P2860

Q34193953-1B337539-3C48-46C0-B7A2-00B319551F1B

Q34193953-2B017A4B-954A-4FAC-93AB-5D0B9F94B6B6

Q34193953-3C45ADE5-D8F4-409C-855A-587C7C085945

Q34193953-4C2CEF2B-208E-4D2F-8309-116E1D3962DC

Q34193953-4E0F678C-D3CD-4787-906E-86F053241A1B

Q34193953-58AE34B0-6F1D-4D41-B590-377FE38FD594

Q34193953-58FFDF40-6AD4-458A-879E-38D148AC961E

Q34193953-604CD434-5AE4-4CCA-A3A0-0410CD346A9C

Q34193953-9471689D-C66E-4104-84F5-0FFE415EC963

Q34193953-96CB4C38-324D-4FE9-A865-792AE7D01F85

P304

Q34193953-43BCEBE7-B8E2-464C-853D-564483EE0F5E

P31

Q34193953-9192E6CF-FAA5-4D6E-944C-7C49968A1F8F

P356

Q34193953-F8C2CF60-8B3E-43B3-BC8C-32AC0A3D043F

P407

Q34193953-ECE733D0-BB64-4DCB-9BDE-89D8D80013D1

P433

Q34193953-A984E721-12E1-485D-99F3-8EBCA3F5675B

P478

Q34193953-96CF0187-1479-41FD-9AF3-BE525F95B625

P50

Q34193953-8AF6003F-B332-4419-A69C-CA0F7D5DA698

Q34193953-B58CB1AE-88C5-4FE4-8CB8-2824FECB3F72

Q34193953-E0A164D6-1DFE-4AD7-BD1E-3EEED5DBDAE5

Q34193953-F69C9455-58A1-4E98-84A0-D44A4DCA7AAB

P577

Q34193953-C07DC2B9-15B8-424C-9679-C9805703387C

P698

Q34193953-07C9DCA4-80A9-49CB-954C-396EEE7E924E

P921

Q34193953-0331425B-E3E8-41C5-B658-E905A9910EDC

Q34193953-28D165DE-8FE0-4F4E-B2BA-C660CB8AB20E

P932

Q34193953-57CC6FDA-B786-41C0-8D19-7AE62E303BB4

P356

JCO.2010.29.2904

P1433

Journal of Clinical Oncology

P1476

Prognostic significance of p16 ...... on TROG 02.02 phase III trial.

@en

P2093

Ben Solomon

http://www.w3.org/2001/XMLSchema#string

Danny Rischin

http://www.w3.org/2001/XMLSchema#string

Jimin Choi

http://www.w3.org/2001/XMLSchema#string

Lester J Peters

http://www.w3.org/2001/XMLSchema#string

Quynh-Thu Le

http://www.w3.org/2001/XMLSchema#string

Richard Fisher

http://www.w3.org/2001/XMLSchema#string

Richard J Young

http://www.w3.org/2001/XMLSchema#string

P2860

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.

Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients

Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.

Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins.

P304

4142-4148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.29.2904

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Brian O'Sullivan

P577

2010-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20697079

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

2953971

http://www.w3.org/2001/XMLSchema#string